FindTrial
Sign In

Low molecular weight heparin (LMWH)

DRUG8 trials

Sponsors

GlaxoSmithKline, Cardiff University, Bristol-Myers Squibb, Major Extremity Trauma Research Consortium, Bayer

Conditions

Blood ClotCancerCarcinoma, Non-small-Cell LungDeep Vein ThrombosisHip FracturesProphylaxis of Recurrent Venous Thromboembolism in Cancer PatientsPulmonary EmbolusThrombosis

Phase 2

Anticoagulation Length in Cancer Associated Thrombosis
TerminatedNCT01817257
Cardiff UniversityCancer, Deep Vein Thrombosis, Pulmonary Embolus +2
Start: 2013-12-31End: 2015-02-28Updated: 2018-10-29
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
CompletedNCT02981472
Bristol-Myers SquibbThrombosis
Start: 2017-01-19End: 2021-10-18Updated: 2022-10-03
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
RecruitingNCT05498428
Janssen Research & Development, LLCCarcinoma, Non-small-Cell Lung
Start: 2022-11-11End: 2028-08-18Target: 520Updated: 2026-02-13

Phase 3

PREVENTion of Clot in Orthopaedic Trauma
CompletedNCT02984384
Major Extremity Trauma Research ConsortiumBlood Clot, Trauma
Start: 2017-04-24End: 2022-02-18Updated: 2024-05-14

Unknown Phase

Hemorrhage Risk Prescribed Arixtra
CompletedNCT01064362
GlaxoSmithKlineThrombosis, Venous
Start: 2010-01-31End: 2010-06-30Updated: 2015-05-12
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
CompletedNCT04979780
BayerProphylaxis of Recurrent Venous Thromboembolism in Cancer Patients, Treatment of Venous Thromboembolism in Cancer Patients
Start: 2021-07-20End: 2022-03-31Updated: 2024-10-31
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
CompletedNCT05150938
BayerTreatment of Venous Thromboembolism in Cancer Patients
Start: 2022-03-18End: 2023-02-28Updated: 2023-12-18
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Not yet recruitingNCT06937372
Queen Mary University of LondonHip Fractures, Venous Thromboembolism (VTE)
Start: 2026-08-01End: 2028-04-30Target: 21194Updated: 2026-01-06

Related Papers

Pharmacometric analyses supporting apixaban doses in neonates with venous thromboembolism
Blood2025-11-03
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
Journal of Clinical Oncology2024-06-058 citations
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
2024-05-121 citations
6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
ESMO Open2024-03-012 citations
Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease
Journal of the American College of Cardiology2023-12-0136 citations
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
CPT Pharmacometrics & Systems Pharmacology2023-03-029 citations
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
JACC CardioOncology2023-02-0714 citations
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
New England Journal of Medicine2023-01-18135 citations
Addendum to British Society for Haematology guideline on the investigation, management and prevention of venous thrombosis in children (<i>Br. J. Haematol</i>. 2011; 154: 196–207)
British Journal of Haematology2021-08-308 citations
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients
BMJ Open2021-03-0128 citations
Which orthopaedic trauma patients are likely to refuse to participate in a clinical trial? A latent class analysis
BMJ Open2019-10-016 citations
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
2015-10-0120 citations